Posted in MIMS/UK
01 October 2010
The marketing authorisation for Cervarix has been updated to show that it offers broader protection against human papillomavirus (HPV) than first thought.
Cervarix was originally indicated to protect against only the two HPV types it contains—16 and 18—which are collectively responsible for around 70 per cent of all cervical cancer cases. Now, however, its licence has been amended to indicate that the vaccine also provides cross-protection against strains 31, 33 and 45—accounting for a further 10 per cent of cases.
Read the entire article here.